MedTrace Logo

XIENCE PRIME SV Everolimus Eluting Coronary Stent Japan Post Marketing Surveillance (XIENCE PRIME SV Japan PMS)

NCT02513719 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 312

Last updated 2024-04-04

Study results available
· View outcomes & findings →

Summary

The objective of the study is to evaluate the safety and efficacy of XIENCE PRIME SV in real world practice in Japanese hospitals.

Conditions

Interventions

DEVICE

XIENCE PRIME SV Everolimus Eluting Coronary Stent

Patients receiving XIENCE PRIME SV Everolimus Eluting Stent

Sponsors & Collaborators

  • Abbott Medical Devices

    lead INDUSTRY

Principal Investigators

  • Ken Kozuma, MD · Teikyo University Hospital, Tokyo

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-05-13
Primary Completion
2019-09-30
Completion
2019-09-30

Countries

  • Japan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02513719 on ClinicalTrials.gov